Lysozyme: a brief review

M. AFZAL MIR
M.B., D.C.H., M.R.C.P.

University Department of Cardiology, Manchester Royal Infirmary, Manchester M13 9WL

Summary

Serum lysozyme (muramidase) estimation is a simple, convenient and useful laboratory investigation. A review of the literature shows that lysozyme has been implicated as an aetiological factor in various disorders, and credited with being a prognostic indicator in acute myeloid leukaemia, but these promises have not been fulfilled. This low molecular weight protein is found in the urine of some patients with renal tubular disorders, but some workers have emphasized its importance as a causal agent in hypokalaemia of acute myeloid leukaemia. Research should be concentrated on muramidase as an expression of cell functions rather than as an aetiological factor. Hypokalaemia in acute myeloid leukaemia may be caused by an unidentified substance of molecular weight similar to that of lysozyme.

Fleming discovered a ‘remarkable bacteriolytic element in tissues and secretions’ in 1922 and called it lysozyme (muramidase). He is reputed to have said, ‘We shall hear more about lysozyme’ (Osserman, 1975). A truly remarkable foresight but even he could not have imagined that in the next 54 years lysozyme would be associated with any abnormality that happens to be associated with an elevated level of this low molecular weight protein.

An increased lysozyme activity in the gastric juice of patients with peptic ulcer prompted Meyer et al. (1948b) to suggest a causal relationship between the two. Although Fleming had already demonstrated lysozyme in the intestines, its increased activity in the colonic secretions of patients with ulcerative colitis and regional enteritis, induced some workers (Meyer et al., 1948a; Prudden, Lane and Levison, 1949a) to postulate that lysozyme was an aetiological factor in these disorders. Further work by Prudden, Lane and Meyer (1949b) and by others (Hiatt et al., 1952) showed that a large population of granulocytes was responsible for the increased concentration of lysozyme in colonic mucus. It is now known that granulocytes and macrophages elaborate lysozyme, and its increased concentration in colonic exudate is secondary to an increased invasion of colon by these cells, as would be expected in inflammatory conditions such as ulcerative colitis and Crohn’s disease.

Osserman and Lawlor (1966) in their excellent paper on lysozyme reported that some of their patients with acute myeloid leukaemia had hypokalaemia and excreted large quantities of lysozyme in the urine. These authors thought the two abnormalities were probably related. Muggia et al. (1969) found hyperkaluria in some leukaemic patients with hypokalaemia and lysozymuria, and they suggested that lysozyme was probably responsible for renal potassium wasting and hypokalaemia. Pickering and Catovsky (1973) found a significant negative correlation between serum K and serum lysozyme but Pruzanski and Platts (1973) found no correlation between hypokalaemia and urinary or serum lysozyme. Mir and his co-workers (1975a) carried out potassium balance studies in thirty-two patients with acute myeloid leukaemia; twelve had hyperkaluria but only seven of these had lysozymuria.

While the aetiological significance of lysozyme in leukaemic patients with hypokalaemia remained unsettled, some workers have examined their data to see if lysozyme has any prognostic value. Wiernik and Serpick (1969) found that patients with acute myeloid leukaemia, who had elevated initial serum muramidase levels, fared worse than those with normal or low levels. Castro, Perilli and Finch (1970) came to the opposite conclusion: they reported that patients with high serum lysozyme levels live longer than those with low levels. Currie (1976) attached prophetic significance to serum lysozyme in acute myeloid leukaemia. He was able to divide his eighty-eight patients into three groups; all nineteen patients with serum lysozyme less than 15 μg/ml (normal 5.1–9.7 μg/ml) failed to achieve remission, all ten patients with levels above 85 μg/ml responded to antileukaemic treatment, and the patients with serum lysozyme in between these two extremes did moderately well. Other workers have failed to confirm these findings (Mir, 1976; McCarthy et al., 1976).

Lysozyme has been employed as a diagnostic tool by some workers: Falchuk, Perrotto and Isselbacher (1975a) found raised serum levels in Crohn’s disease but not in ulcerative colitis. Pancytopenia can be a difficult diagnostic problem and serum lysozyme level has been used to differentiate between aleukaemic leukaemia (high) and aplastic anaemia (low).
(Firkin, 1972). Raised lysozyme levels have also been reported in pancytopenia of megaloblastic anaemia (Perillie, Kaplan and Finch, 1967). An elevated serum lysozyme level can often be helpful in distinguishing acute myeloid leukaemia from acute lymphatic leukaemia, which is associated with low lysozyme activity (Jolles, Steinberg and Mathe, 1965; Perillie et al., 1968).

The diagnostic value of lysozyme is not invariable since an elevated serum level is not always found in conditions known to have high lysozyme activity. The inadequacy of morphological and histochemical techniques is not always helped by a simple lysozyme estimation in a difficult diagnostic problem of blastemaemia: low serum lysozyme level may be invariable in acute lymphatic leukaemia but low levels are also common in acute myeloid leukaemia (Osserman and Lawlor, 1966; Perillie et al., 1968; Mir et al., 1975a; Currie, 1976; Mir, 1976). Uncertainty also accompanies the diagnostic use of lysozyme in inflammatory bowel disorders: Falchuk et al. (1975a) found raised serum levels in Crohn's disease but not in ulcerative colitis; Pounder et al. (1975) found raised levels in both conditions while Peters, Geboes and Vantrappen (1975), and Johansson and Ursing (1976) did not find elevated levels in either disease. These discrepancies could be caused by differences in methods, in patient population as well as in the stages of disease during which the patients were studied by various workers.

The differences in methodology apart, it seems quite acceptable that serum lysozyme level should be elevated in the active phase of Crohn's disease as shown by Falchuk, Perrotto and Isselbacher (1975b), as there is an increased infiltration of the bowel by lysozyme producing cells (i.e. macrophages, granulocytes, etc.). An elevated serum level in pancytopenia favours leukaemia rather than aplastic anaemia, and when the morphological features of blast cells are not distinctly helpful, acute myeloid leukaemia is probable in the presence of an elevated serum muramidase level. At present it is difficult to accept that lysozyme is of any prognostic importance because its serum levels may reflect the extent of tumour mass in the body, but we do not know the sensitivity of such a mass to cytotoxic therapy. Future studies may reveal various subtypes of muramidase based on more sophisticated physical and biochemical characteristics, and these subtypes may reveal more about the cell functions and about their sensitivity to antitumour drugs.

The aetiological role of lysozyme in hyperkalaemia and the associated renal tubular dysfunction have been questioned. The involvement of lysozyme was based on the fact that lysozymaemia and hyperkalaemia occurred together in some patients with acute myeloid leukaemia (Osserman and Lawlor, 1966; Muggia et al., 1969; Pickering and Catovsky, 1973). Lysozymuria has been reported in various renal tubular disorders as a manifestation of the disease (Butler and Flyn, 1961; Kazantzis et al., 1963; Prockop and Davidson, 1964; Harrison et al., 1968). Hypokalaemia may occur in patients with normal lysozyme; and high lysozyme levels are not always associated with low serum K levels (Pruzanski and Platts, 1973; Mir et al., 1975a). Klockars et al. (1974) observed proximal renal tubular lesions in chloroleukaemic rats with elevated lysozyme levels, but these workers were unable to reproduce such lesions in normal rats after the intra-aortic administration of lysozyme. Other workers (Rosenthal, Maglio and Moloney, 1972; Greenberger, Rosenthal and Moloney, 1973) have demonstrated in chloroleukaemic and normal rats that only prolonged elevation in serum lysozyme causes lysozymuria and hyperkalaemia. Mason, Howes and Taylor (1975) found no tubular maximum (Tm) for resorption of lysozyme in the perfused rat kidney, and lysozymuria occurred even at low perfusate levels of lysozyme. These workers demonstrated an increased K and Na excretion as the lysozyme concentration was increased in the perfusate. Mack (1975) showed that Tm for lysozyme was about 1000 μg/min but lysozymuria occurred at normal filtered load of 50 μg/min.

How far can these studies in rats be extrapolated to apply to humans? Mir et al. (1975b) correlated total glomerular filtered load with hypokalaemia in seven patients with acute myeloid leukaemia. Three of their patients developed hypokalaemia at lower than normal filtered lysozyme loads. Proximal renal tubular dysfunction has been reported in acute myeloid leukaemia in association with normal serum lysozyme levels (Mir and Delamore, 1974). Leukaemic plasma has been found to inhibit Na efflux from erythrocytes (Mir and Bobinski, 1975). Lysozymuria, hypokalaemia and hyperkalaemia may therefore all be manifestations of widespread renal tubular dysfunction caused by some other unidentified substance of similar molecular weight, released from blast cells, which is nephrotoxic and is excreted by leukaemic patients in their urine.

References


Lysozyme

259


Lysozyme: a brief review.

M. A. Mir

*Postgrad Med J* 1977 53: 257
doi: 10.1136/pgmj.53.619.257

Updated information and services can be found at: [http://pmj.bmj.com/content/53/619/257](http://pmj.bmj.com/content/53/619/257)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)